Adherence to the novel oral anticoagulants: an unmet need

References

• Prandoni P. Venous thromboembolism in 2013: the advent of the novel oral anticoagulants. Nat Rev Cardiol 2014;11:70-2
   PubMed Web of Science ®Google Scholar
• van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124:1968-75
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62
   PubMed Web of Science ®Google Scholar
• Prandoni P, Barbar S, Vedovetto V, et al. Treatment of venous thromboembolism: the single-drug approach. Clin Pract 2013;10:607-13
   Google Scholar
• Prandoni P. The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations. Blood Transfus 2015;13:178-80
   PubMed Web of Science ®Google Scholar
• Verso M, Agnelli G, Prandoni P. Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. Intern Emerg Med 2015;10:651-6
   PubMed Web of Science ®Google Scholar
• Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase the risk of gastrointestinal bleeding – a systematic review and meta-analysis. Ned Tijdschr Geneeskd 2013;145:105-12
   Google Scholar
• Pengo V, Crippa L, Falanga A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. Thromb Haemost 2011;106:868-76
   PubMed Web of Science ®Google Scholar
• Suryanarayan D, Schulman S. When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world – a problem or a myth? Semin Thromb Hemost 2014;40:852-9
   PubMed Web of Science ®Google Scholar
• Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028-35
   PubMed Web of Science ®Google Scholar
• Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thromb Haemost 2012;11:390-4
   Web of Science ®Google Scholar
• van der Meer FJ, Briet E, Vandenbroucke JP, et al. The role of compliance as a cause of instability in oral anticoagulant therapy. Br J Haematol 1997;98:893-900
   PubMed Web of Science ®Google Scholar
• Laporte S, Quenet S, Buchmuller-Cordier A, et al. Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost 2003;89:458-67
   PubMed Web of Science ®Google Scholar
• Orensky IA, Holdford DA. Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy 2005;25:1801-8
   PubMed Web of Science ®Google Scholar
• Kimmel SE, Chen Z, Price M, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) study. Arch Intern Med 2007;167:229-35
   PubMed Web of Science ®Google Scholar
• Parker CS, Chen Z, Price M, et al. Adherence to warfarin assessed by electronic pill caps, clinician assessment and patient reports: results from the IN-RANGE study. J Gen Intern Med 2007;22:1254-9
   PubMed Web of Science ®Google Scholar
• Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010;4:51-60
   PubMed Web of Science ®Google Scholar
• Willey VJ, Bullano MF, Hauch O, et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 2004;26:1149-59
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Sardar P, Giri JS, et al. Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clin Proc 2014;89:896-907
   PubMed Web of Science ®Google Scholar
• Jin J, Sklar GE, Min Sen OV, Chuen LS. Factors affecting therapeutic compliance: a review from the patient’s perspective. Ther Clin Risk Manag 2008;4:269-86
   PubMedGoogle Scholar
• Beyer-Westendorf J, Forster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients – results from the Dresden non-interventional oral anticoagulation registry. Europace 2015;17:530-8
   PubMed Web of Science ®Google Scholar
• Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in ‘real-world’ patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61:2264-73
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Ebertz F, Forster K, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015;113:1247-57
   PubMed Web of Science ®Google Scholar
• Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013;11:1295-9
   PubMed Web of Science ®Google Scholar
• Amin A, Marrs JC. Direct oral anticoagulants for the management of thromboembolic disorders: the importance of adherence and persistence in achieving beneficial outcomes. Clin Applied Thromb Hemost 2015: published online 27 Aug 2015
   Google Scholar
• McHorney C, Crivera C, Laliberté F, et al. Adherence to non-VKA oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Curr Med Res Opin 2015; 10.1185/03007995.2015.1096242
   PubMed Web of Science ®Google Scholar
• Crivera C, Nelson WW, Bookhart B, et al. Pharmacy Quality Alliance Measure: adherence to non-warfarin oral anticoagulant medication. Circ Cardiovasc Qual Outcomes 2015;8(Suppl 2):A366
   Google Scholar
• Laliberté F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in non-valvular atrial fibrillation patients. Curr Med Res Opin 2014;30:1317-25
   PubMed Web of Science ®Google Scholar
• Nelson WW, Song X, Coleman CI, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin 2014;30:2461-9
   PubMed Web of Science ®Google Scholar
• Hoffman A, Galle PR. Gastrointestinal disorders and dabigatran. Scand J Gastroenterol 2013;48:9-16
   PubMed Web of Science ®Google Scholar
• Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012;18:527-39
   PubMed Web of Science ®Google Scholar
• Coleman CI, Roberts MS, Sobieraj DM, et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012;28:669-80
   PubMed Web of Science ®Google Scholar